Literature DB >> 17907217

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

Fernando Perez-Ruiz1, Frédéric Lioté.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17907217     DOI： 10.1002/art.23007

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  43 in total

1.  Quality of care in patients with gout: why is management suboptimal and what can be done about it?

Authors:  N Lawrence Edwards
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

Review 2.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 3.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

4.  A qualitative and quantitative analysis of the characteristics of gout patient education resources.

Authors:  Philip C Robinson; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-01-16       Impact factor: 2.980

5.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

Review 6.  Quality of life and quality of care for patients with gout.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 7.  A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Authors:  Jeannie Chao; Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 8.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

9.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

10.  Adherence with urate-lowering therapies for the treatment of gout.

Authors:  Leslie R Harrold; Susan E Andrade; Becky A Briesacher; Marsha A Raebel; Hassan Fouayzi; Robert A Yood; Ira S Ockene
Journal:  Arthritis Res Ther       Date:  2009-03-27       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.